Lixte Biotechnology Holdings is a biotechnology business based in the US. Lixte Biotechnology Holdings shares (LIXT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.25 – a decrease of 2.34% over the previous week. Lixte Biotechnology Holdings employs 2 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.25 |
|---|---|
| 52-week range | $1.02 - $3.50 |
| 50-day moving average | $1.25 |
| 200-day moving average | $1.85 |
| Wall St. target price | N/A |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.59 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.25 from 2025-05-02
| 1 week (2025-04-25) | -2.34% |
|---|---|
| 1 month (2025-04-04) | 2.81% |
| 3 months (2025-02-05) | -50.20% |
| 6 months (2024-11-05) | -33.86% |
| 1 year (2024-05-03) | -56.75% |
|---|---|
| 2 years (2023-05-04) | -77.10% |
| 3 years (2022-05-04) | 14.2 |
| 5 years (2020-05-04) | 53.394 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -81.88% |
| Return on equity TTM | -148.73% |
| Profit margin | 0% |
| Book value | $-1.19 |
| Market Capitalization | $3.4 million |
TTM: trailing 12 months
We're not expecting Lixte Biotechnology Holdings to pay a dividend over the next 12 months.
You may also wish to consider:
Lixte Biotechnology Holdings's shares were split on a 1:10 basis on 4 June 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lixte Biotechnology Holdings shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Lixte Biotechnology Holdings shares which in turn could have impacted Lixte Biotechnology Holdings's share price.
Over the last 12 months, Lixte Biotechnology Holdings's shares have ranged in value from as little as $1.02 up to $3.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lixte Biotechnology Holdings's is 0.323. This would suggest that Lixte Biotechnology Holdings's shares are less volatile than average (for this exchange).
To put Lixte Biotechnology Holdings's beta into context you can compare it against those of similar companies.
Lixte Biotechnology Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.